Company intelligence / Profile preview

Chengdu Huasun Technology Group

Chengdu, Sichuan, China

Ownership: Private
Employees: ~918
Development stage: Other

Overview

Chengdu Huasun Technology Group is a diversified Chinese biopharma company with commercialized drugs including traditional Chinese medicines, chemical drugs, monoclonal antibodies, and radiolabeled biologics. Notable approvals include Iodine [131I] Metuximab for hepatocellular carcinoma and San qi Tongshu Capsule for stroke. The company also develops animal health pharmaceuticals and operates a steel structure construction business. Clinical results are not detailed in public English-language sources.

Therapeutic areas: CardiovascularNeurologyOncology
Modalities: Small moleculeHerbal medicineMonoclonal antibodyRadiolabeled antibodyTherapeutic radiopharmaceuticalsProtein
Industry: Biotech

Beyond the preview

Go deeper on Chengdu Huasun Technology Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Huasun Technology Group.

Explore the full profile